These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18977723)

  • 41. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
    Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
    AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
    Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
    HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan.
    Lai CC; Hung CC; Chen MY; Sun HY; Lu CL; Tseng YT; Chang SF; Su YC; Liu WC; Hsieh CY; Wu PY; Chang SY; Chang SC
    J Antimicrob Chemother; 2012 May; 67(5):1254-60. PubMed ID: 22302562
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
    Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
    Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
    Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
    AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012.
    Yang WL; Kouyos R; Scherrer AU; Böni J; Shah C; Yerly S; Klimkait T; Aubert V; Furrer H; Battegay M; Cavassini M; Bernasconi E; Vernazza P; Held L; Ledergerber B; Günthard HF;
    J Infect Dis; 2015 Jul; 212(1):28-38. PubMed ID: 25576600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequency and diversity of human immunodeficiency virus type 1 mutations associated with antiretroviral resistance among patients from Southern Brazil failing highly active antiretroviral therapy (HAART).
    Figueiredo Saad F; Kaminami Morimoto H; Wiechmann SL; Bonametti AM; Ueda LT; Matsuo T; Reiche EM
    Int J Mol Med; 2010 Oct; 26(4):585-93. PubMed ID: 20818500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.
    Bannister WP; Cozzi-Lepri A; Kjær J; Clotet B; Lazzarin A; Viard JP; Kronborg G; Duiculescu D; Beniowski M; Machala L; Phillips A;
    J Antimicrob Chemother; 2011 Apr; 66(4):901-11. PubMed ID: 21393179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A pilot study of health beliefs and attitudes concerning measures of antiretroviral adherence among prisoners receiving directly observed antiretroviral therapy.
    White BL; Wohl DA; Hays RD; Golin CE; Liu H; Kiziah CN; Simpson G; Kaplan AH
    AIDS Patient Care STDS; 2006 Jun; 20(6):408-17. PubMed ID: 16789854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increasing prevalence of resistance mutations in antiretroviral-naïve individuals with established HIV-1 infection from 1996-2001 in St. Louis.
    Ristig MB; Arens MQ; Kennedy M; Powderly W; Tebas P
    HIV Clin Trials; 2002; 3(2):155-60. PubMed ID: 11976994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.
    Sax PE; Islam R; Walensky RP; Losina E; Weinstein MC; Goldie SJ; Sadownik SN; Freedberg KA
    Clin Infect Dis; 2005 Nov; 41(9):1316-23. PubMed ID: 16206108
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Limited spending: an analysis of correctional expenditures on antiretrovirals for HIV-infected prisoners.
    Zaller N; Thurmond P; Rich JD
    Public Health Rep; 2007; 122(1):49-54. PubMed ID: 17236608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City.
    Gagliardo C; Brozovich A; Birnbaum J; Radix A; Foca M; Nelson J; Saiman L; Yin M; Carras-Terzian E; West E; Neu N
    Clin Infect Dis; 2014 Mar; 58(6):865-72. PubMed ID: 24429431
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of antiretroviral resistance in HIV-1.
    Cavert W; Balfour HH
    Clin Lab Med; 2003 Dec; 23(4):915-28. PubMed ID: 14711099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa.
    Zhang Y; Fogel JM; Guo X; Clarke W; Breaud A; Cummings V; Hamilton EL; Ogendo A; Kayange N; Panchia R; Dominguez K; Chen YQ; Sandfort T; Eshleman SH
    AIDS; 2018 Jun; 32(10):1301-1306. PubMed ID: 29794492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy.
    Orrell C; Levison J; Ciaranello A; Bekker LG; Kuritzkes DR; Freedberg KA; Wood R
    Pediatr Infect Dis J; 2013 Jun; 32(6):644-7. PubMed ID: 23303240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs.
    Evaluation of Resistance Assays (ERA) Trial Investigators
    HIV Clin Trials; 2005; 6(4):183-6. PubMed ID: 16214734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concurrent Anemia and Elevated C-Reactive Protein Predicts HIV Clinical Treatment Failure, Including Tuberculosis, After Antiretroviral Therapy Initiation.
    Shivakoti R; Yang WT; Gupte N; Berendes S; Rosa AL; Cardoso SW; Mwelase N; Kanyama C; Pillay S; Samaneka W; Riviere C; Sugandhavesa P; Santos B; Poongulali S; Tripathy S; Bollinger RC; Currier JS; Tang AM; Semba RD; Christian P; Campbell TB; Gupta A;
    Clin Infect Dis; 2015 Jul; 61(1):102-10. PubMed ID: 25828994
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fostemsavir resistance-associated polymorphisms in HIV-1 subtype C in a large cohort of treatment-naïve and treatment-experienced individuals in Botswana.
    Zuze BJL; Radibe BT; Choga WT; Bareng OT; Moraka NO; Maruapula D; Seru K; Mokgethi P; Mokaleng B; Ndlovu N; Kelentse N; Pretorius-Holme M; Shapiro R; Lockman S; Makhema J; Novitsky V; Seatla KK; Moyo S; Gaseitsiwe S
    Microbiol Spectr; 2023 Dec; 11(6):e0125123. PubMed ID: 37823653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.